Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report

James A. Fletcher M.B.B.S. , William J. Mullally MBBCh BAO , Rahul Ladwa MPhil , Kenneth J. O’Byrne MD
{"title":"Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report","authors":"James A. Fletcher M.B.B.S. ,&nbsp;William J. Mullally MBBCh BAO ,&nbsp;Rahul Ladwa MPhil ,&nbsp;Kenneth J. O’Byrne MD","doi":"10.1016/j.jtocrr.2023.100591","DOIUrl":null,"url":null,"abstract":"<div><p><em>ALK</em> gene rearrangements are detected in approximately 3% to 5% of NSCLC. <em>ALK</em> tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in <em>ALK</em>-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after <em>ALK</em> tyrosine kinase inhibitors–induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 2","pages":"Article 100591"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001340/pdfft?md5=bd98224b5ca00552f89132e9ae085664&pid=1-s2.0-S2666364323001340-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after ALK tyrosine kinase inhibitors–induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿来替尼诱发肺炎后的罗拉替尼:病例报告
在大约3%至5%的NSCLC中可检测到ALK基因重排。ALK酪氨酸激酶抑制剂(如第三代劳拉替尼等)对ALK基因重排的NSCLC有显著疗效;但它们与治疗限制性和潜在致命的药物诱发间质性肺病(ILD)的低发生率有关。有人担心这可能是一种类药物效应,一些病例报告也支持这一理论。由于临床试验的排除标准,目前用于指导 ALK 酪氨酸激酶抑制剂诱发 ILD 后决策的前瞻性数据非常有限。我们对文献进行了系统性回顾,结果只发现了四例有关lorlatinib在这种情况下安全性的报道。在此,我们报告了一位因3级药物诱导的ILD而停用阿来替尼的患者成功进行了lorlatinib排序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
期刊最新文献
First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report A Response to the Letter to the Editor: “Heart and Lung Dose as Predictors of Overall Survival in Patients With Locally Advanced Lung Cancer: A National Multicenter Study” Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer Brief Report of a New Anatomical Region at Risk in Thoracic Radiotherapy: From Discovery to Implementation Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1